# CHRYSALIS (NCT02609776)

> Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02609776
- Phase: PHASE1
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Janssen Research & Development, LLC
- Conditions: Non-Small-Cell Lung Cancer
- Interventions: Amivantamab; Amivantamab; Lazertinib; Carboplatin; Pemetrexed
- Enrollment: 751
- Primary outcome: Part 1: Number of Participants With Dose Limiting Toxicity (DLT)
- Primary outcome: Part 2: Number of Participants With Adverse Events (AEs) and Serious AEs
- Primary outcome: Part 2: Overall Response Rate (ORR)
- Primary outcome: Part 2: Duration of Response (DOR)
- Primary outcome: Part 2: Percentage of Participants With Clinical Benefit
- Primary outcome: Trough Serum Concentration (Ctrough) of Amivantamab
- Primary outcome: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Amivantamab

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 30
- Podcasts: 25
- YouTube: 24

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=chrysalis-nct02609776

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02609776", "email": "<work email>"}; the inbox owner confirms by the emailed link.